Hendley & Co. Inc. Takes Position in AstraZeneca PLC $AZNCF

Hendley & Co. Inc. acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 4th quarter, Holdings Channel.com reports. The firm acquired 64,805 shares of the company’s stock, valued at approximately $11,373,000. AstraZeneca comprises approximately 4.0% of Hendley & Co. Inc.’s portfolio, making the stock its 9th largest position.

Several other institutional investors and hedge funds have also made changes to their positions in AZNCF. Boston Common Asset Management LLC lifted its position in shares of AstraZeneca by 5.6% in the third quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock valued at $28,992,000 after acquiring an additional 10,154 shares in the last quarter. Saranac Partners Ltd purchased a new stake in shares of AstraZeneca in the third quarter valued at $876,000. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $46,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of AstraZeneca in the fourth quarter valued at $144,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

Shares of OTCMKTS:AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a 52-week low of $122.26 and a 52-week high of $195.00. The stock’s fifty day simple moving average is $187.10 and its 200-day simple moving average is $183.70.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.